

James M Stone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8641549/james-m-stone-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136 papers	7,575 citations	47 h-index	85 g-index
156 ext. papers	9,242 ext. citations	5 avg, IF	6.14 L-index

#	Paper	IF	Citations
136	The prevalence and incidence of irritable bowel syndrome and inflammatory bowel disease in depression and bipolar disorder: a systematic review and meta-analysis.. <i>Psychosomatic Medicine</i> , 2022 ,	3.7	3
135	Impact of COVID-19 on mental health research: is this the breaking point?. <i>British Journal of Psychiatry</i> , 2022 , 1-3	5.4	1
134	Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function. <i>Translational Psychiatry</i> , 2021 , 11, 579	8.6	1
133	Resting-state connectivity studies as a marker of the acute and delayed effects of subanaesthetic ketamine administration in healthy and depressed individuals: A systematic review. <i>Brain and Neuroscience Advances</i> , 2021 , 5, 23982128211055426	4	0
132	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. <i>Molecular Psychiatry</i> , 2021 , 26, 2590-2604	15.1	7
131	GABA, Glutamate and Neural Activity: A Systematic Review With Meta-Analysis of Multimodal H-MRS-fMRI Studies. <i>Frontiers in Psychiatry</i> , 2021 , 12, 644315	5	7
130	Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes. <i>Neuropsychopharmacology</i> , 2021 , 46, 1468-1474	8.7	6
129	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data. <i>JAMA Psychiatry</i> , 2021 , 78, 667-681	14.5	21
128	The Effects of Acute Δ^9 Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021 , 6, 660-667	3.4	
127	Brain volume in chronic ketamine users - relationship to sub-threshold psychotic symptoms and relevance to schizophrenia. <i>Psychopharmacology</i> , 2021 , 1	4.7	0
126	Ketamine: A tale of two enantiomers. <i>Journal of Psychopharmacology</i> , 2021 , 35, 109-123	4.6	31
125	Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis. <i>Human Brain Mapping</i> , 2021 , 42, 439-451	5.9	0
124	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. <i>Biological Psychiatry</i> , 2021 , 90, 9-15	7.9	6
123	Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021 , 47, 662-671	1.3	10
122	Ketamine for depression. <i>International Review of Psychiatry</i> , 2021 , 33, 207-228	3.6	2
121	Updated Review and Meta-Analysis of Probiotics for the Treatment of Clinical Depression: Adjunctive vs. Stand-Alone Treatment. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	19
120	Imaging Brain Glx Dynamics in Response to Pressure Pain Stimulation: A H-fMRS Study. <i>Frontiers in Psychiatry</i> , 2021 , 12, 681419	5	0

119	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. <i>Translational Psychiatry</i> , 2021 , 11, 425	8.6	2
118	Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis. <i>JAMA Psychiatry</i> , 2021 , 78, 1343-1354	14.5	47
117	Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study. <i>Journal of Psychopharmacology</i> , 2020 , 34, 648-653	4.6	3
116	Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome. <i>Schizophrenia Bulletin</i> , 2020 , 46, 670-679	1.3	12
115	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020 , 34, 3-78	4.6	85
114	Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia. <i>Psychopharmacology</i> , 2020 , 237, 443-451	4.7	8
113	T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020 , 46, S238-S238	1.3	78
112	M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S198-S198	1.3	78
111	Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development. <i>Schizophrenia Research</i> , 2020 , 223, 59-70	3.6	12
110	Neutrophil-lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records. <i>BMJ Open</i> , 2020 , 10, e036859	3	12
109	Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study. <i>Neuropsychopharmacology</i> , 2020 , 45, 641-648	8.7	16
108	O10.3. EXPOSURE TO COMMON INFECTIOUS PATHOGENS IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS: CLINICAL AND IMMUNOBIOLOGICAL ASSOCIATIONS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S190-S191	1.3	78
107	Inflammation, Glutamate, and Cognition in Bipolar Disorder Type II: A Proof of Concept Study. <i>Frontiers in Psychiatry</i> , 2019 , 10, 66	5	10
106	A systematic review on neuropsychological function in bipolar disorders type I and II and subthreshold bipolar disorders-something to think about. <i>CNS Spectrums</i> , 2019 , 24, 127-143	1.8	7
105	F94. EFFECTS OF OXYTOCIN ON NEUROCHEMICAL METABOLITES IN PSYCHOSIS RISK. <i>Schizophrenia Bulletin</i> , 2019 , 45, S289-S290	1.3	78
104	O5.6. REMISSION FROM ANTIPSYCHOTIC TREATMENT IN FIRST EPISODE PSYCHOSIS RELATED TO LONGITUDINAL CHANGES IN BRAIN GLUTAMATE LEVELS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S175-S175	1.3	78
103	O7.3. ALTERED HIPPOCAMPAL-STRIATAL-MIDBRAIN FUNCTION IN SUBJECTS AT CLINICAL HIGH RISK OF PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S180-S180	1.3	78
102	Neurochemical effects of oxytocin in people at clinical high risk for psychosis. <i>European Neuropsychopharmacology</i> , 2019 , 29, 601-615	1.2	4

101	Altered relationship between prefrontal glutamate and activation during cognitive control in people with high trait anxiety. <i>Cortex</i> , 2019 , 117, 53-63	3.8	13
100	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2019 , 85, 79-87	7.9	36
99	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. <i>NPJ Schizophrenia</i> , 2019 , 5, 12	5.5	12
98	Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis. <i>Frontiers in Psychiatry</i> , 2019 , 10, 254	5	7
97	Gut feeling: randomized controlled trials of probiotics for the treatment of clinical depression: Systematic review and meta-analysis. <i>Therapeutic Advances in Psychopharmacology</i> , 2019 , 9, 20451253198399637	4.9	37
96	Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential. <i>American Journal of Psychiatry</i> , 2019 , 176, 966	11.9	8
95	O13.5. GLUTAMATERGIC METABOLITES ASSOCIATED WITH ALTERED HIPPOCAMPAL AND STRIATAL ACTIVATION DURING NOVELTY SALIENCE IN PEOPLE WITH A CLINICAL HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019 , 45, S202-S203	1.3	78
94	Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task. <i>European Neuropsychopharmacology</i> , 2019 , 29, 222-234	1.2	9
93	Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2019 , 76, 199-207	14.5	41
92	Clinical and demographic differences between patients with manic, depressive and schizophrenia-spectrum psychoses presenting to Early Intervention Services in London. <i>Microbial Biotechnology</i> , 2019 , 13, 509-516	3.3	2
91	Negative symptoms in first-episode psychosis: Clinical correlates and 1-year follow-up outcomes in London Early Intervention Services. <i>Microbial Biotechnology</i> , 2019 , 13, 443-452	3.3	11
90	Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders. <i>Schizophrenia Bulletin</i> , 2019 , 45, 233-246	1.3	14
89	Determinants of treatment response in first-episode psychosis: an F-DOPA PET study. <i>Molecular Psychiatry</i> , 2019 , 24, 1502-1512	15.1	78
88	Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 114-119	5.8	24
87	S12. THE AUTOANTIBODYOME IN PSYCHOSIS: A PILOT STUDY AND BLUEPRINT FOR BIOMARKER DISCOVERY. <i>Schizophrenia Bulletin</i> , 2018 , 44, S328-S328	1.3	78
86	Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis. <i>Neuropsychopharmacology</i> , 2018 , 43, 2652-2659	8.7	23
85	Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia. <i>Journal of Psychopharmacology</i> , 2018 , 32, 497-508	4.6	26
84	Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. <i>Psychopharmacology</i> , 2018 , 235, 3045-3054	4.7	16

83	Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre H-MRS study (OPTiMiSE). <i>Molecular Psychiatry</i> , 2018 , 23, 2145-2155	15.1	70
82	The blood-brain barrier in psychosis. <i>Lancet Psychiatry</i> , 2018 , 5, 79-92	23.3	123
81	Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review. <i>European Neuropsychopharmacology</i> , 2018 , 28, 1289-1304	1.2	14
80	First-generation second-generation long-acting injectable antipsychotic drugs and time to relapse. <i>Therapeutic Advances in Psychopharmacology</i> , 2018 , 8, 333-336	4.9	9
79	Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort. <i>Schizophrenia Bulletin</i> , 2018 , 44, 1323-1331	1.3	38
78	The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. <i>Lancet Psychiatry</i> , 2018 , 5, 816-823	23.3	54
77	O3.7. EFFECT OF N-ACETYLCYSTEINE ON BRAIN GLUTAMATE LEVELS AND RESTING PERFUSION IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018 , 44, S81-S82	1.3	78
76	Reply to: Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?. <i>Psychological Medicine</i> , 2017 , 47, 983	6.9	
75	4.3 Functional Magnetic Resonance Spectroscopy in Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017 , 43, S5-S5	1.3	78
74	15. Neuronal Autoantibodies and Blood-Brain Barrier Disruption in Subjects at Ultra-High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2017 , 43, S12-S12	1.3	78
73	74. The Neurochemical Basis of Antipsychotic Response in Psychosis: A Prospective Multimodal 18 F-Dopa and 1-H MRS Study in First-Episode Psychosis.. <i>Schizophrenia Bulletin</i> , 2017 , 43, S43-S43	1.3	78
72	60.4 Multimodal Evidence of GABAergic Circuit Dysfunction in People at Clinical High Risk of Psychosis. <i>Schizophrenia Bulletin</i> , 2017 , 43, S35-S35	1.3	78
71	3.4 GABA Interneuron Dysfunction and the Onset of Psychosis. <i>Schizophrenia Bulletin</i> , 2017 , 43, S3-S4	1.3	1
70	SA83. Brain Glutamate Levels and Antipsychotic Response in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017 , 43, S142-S143	1.3	5
69	An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications. <i>Comprehensive Psychiatry</i> , 2016 , 66, 39-45	7.3	8
68	Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. <i>Schizophrenia Bulletin</i> , 2016 , 42, 744-52	1.3	120
67	Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression?. <i>PeerJ</i> , 2016 , 4, e1710	3.1	28
66	The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. <i>Psychological Medicine</i> , 2016 , 46, 3443-3450	6.9	23

65	HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis. <i>Translational Psychiatry</i> , 2016 , 6, e797	8.6	18
64	Delta-9-tetrahydrocannabinol, neural oscillations above 20Hz and induced acute psychosis. <i>Psychopharmacology</i> , 2015 , 232, 519-28	4.7	20
63	Sensorimotor gating, cannabis use and the risk of psychosis. <i>Schizophrenia Research</i> , 2015 , 164, 21-7	3.6	9
62	Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study. <i>Psychopharmacology</i> , 2015 , 232, 4515-24	4.7	21
61	Drug models of schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2015 , 5, 43-58	4.9	88
60	Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe. <i>Journal of Psychopharmacology</i> , 2015 , 29, 1025-8	4.6	17
59	Glutamate and dopamine in schizophrenia: an update for the 21st century. <i>Journal of Psychopharmacology</i> , 2015 , 29, 97-115	4.6	428
58	Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. <i>Psychopharmacology</i> , 2014 , 231, 2107-16	4.7	27
57	Tobacco smoking in schizophrenia: investigating the role of incentive salience. <i>Psychological Medicine</i> , 2014 , 44, 2189-97	6.9	10
56	Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. <i>Biological Psychiatry</i> , 2014 , 75, e11-3	7.9	218
55	Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. <i>Neuropsychopharmacology</i> , 2014 , 39, 2891-9	8.7	69
54	Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. <i>Psychological Medicine</i> , 2014 , 44, 499-506	6.9	50
53	Cannabis use and transition to psychosis in people at ultra-high risk. <i>Psychological Medicine</i> , 2014 , 44, 2503-12	6.9	60
52	Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation. <i>Frontiers in Psychiatry</i> , 2014 , 5, 149	5	45
51	Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. <i>Psychological Medicine</i> , 2014 , 44, 3491-501	6.9	31
50	Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use. <i>Psychopharmacology</i> , 2013 , 225, 41-50	4.7	11
49	Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. <i>Journal of Psychopharmacology</i> , 2013 , 27, 771-8	4.6	31
48	Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. <i>Journal of Psychopharmacology</i> , 2013 , 27, 19-27	4.6	287

47	When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia. <i>British Journal of Psychiatry</i> , 2013 , 202, 91-3	5.4	19
46	Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. <i>Schizophrenia Bulletin</i> , 2013 , 39, 1343-51	1.3	148
45	Substance use and regional gray matter volume in individuals at high risk of psychosis. <i>European Neuropsychopharmacology</i> , 2012 , 22, 114-22	1.2	17
44	Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. <i>Molecular Psychiatry</i> , 2012 , 17, 664-5	15.1	209
43	Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2138-43	11.5	555
42	Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. <i>Neuropsychopharmacology</i> , 2012 , 37, 2515-21	8.7	130
41	Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence. <i>Molecular Psychiatry</i> , 2012 , 17, 568-9	15.1	16
40	Glutamate and psychosis risk. <i>Current Pharmaceutical Design</i> , 2012 , 18, 466-78	3.3	32
39	Cannabis in the arm: what can we learn from intravenous cannabinoid studies?. <i>Current Pharmaceutical Design</i> , 2012 , 18, 4906-14	3.3	9
38	The glutamate hypothesis of schizophrenia: neuroimaging and drug development. <i>Current Pharmaceutical Biotechnology</i> , 2012 , 13, 1500-12	2.6	43
37	Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. <i>Biological Psychiatry</i> , 2011 , 69, 97-9	7.9	53
36	Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. <i>Biological Psychiatry</i> , 2011 , 69, 495-503	7.9	108
35	Reply to: Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis. <i>Biological Psychiatry</i> , 2011 , 70, e3-e4	7.9	
34	Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. <i>Archives of General Psychiatry</i> , 2011 , 68, 881-90		106
33	Disruption of frontal coherence by Δ -tetrahydrocannabinol is associated with positive psychotic symptoms. <i>Neuropsychopharmacology</i> , 2011 , 36, 827-36	8.7	68
32	Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. <i>Human Psychopharmacology</i> , 2011 , 26, 77-80	2.3	28
31	Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation. <i>Pharmacopsychiatry</i> , 2011 , 44, 33-48	2	13
30	Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. <i>Archives of General Psychiatry</i> , 2011 , 68, 489-95		196

29	Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?. <i>Therapeutic Advances in Psychopharmacology</i> , 2011 , 1, 5-18	4.9	43
28	Review: The biological basis of antipsychotic response in schizophrenia. <i>Journal of Psychopharmacology</i> , 2010 , 24, 953-64	4.6	36
27	Delta-9-tetrahydrocannabinol disruption of time perception and of self-timed actions. <i>Pharmacopsychiatry</i> , 2010 , 43, 236-7	2	10
26	Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. <i>Biological Psychiatry</i> , 2010 , 68, 599-602	7.9	107
25	Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. <i>Neuropsychopharmacology</i> , 2010 , 35, 764-74	8.7	481
24	Cannabis and psychosis. <i>British Journal of Psychiatry</i> , 2010 , 197, 333	5.4	
23	Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia - relationship to auditory event-related potentials. <i>Psychiatry Research - Neuroimaging</i> , 2010 , 183, 174-6	2.9	21
22	Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. <i>Schizophrenia Bulletin</i> , 2009 , 35, 789-97	1.3	57
21	Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. <i>Biological Psychiatry</i> , 2009 , 66, 533-9	7.9	185
20	Abnormal thalamic glutamate and liability to psychosis: state or trait marker?. <i>Schizophrenia Research</i> , 2009 , 115, 94-5	3.6	6
19	Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. <i>Current Pharmaceutical Design</i> , 2009 , 15, 2594-602	3.3	63
18	Functional neuroimaging in schizophrenia: diagnosis and drug discovery. <i>Trends in Pharmacological Sciences</i> , 2008 , 29, 91-8	13.2	120
17	Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. <i>Psychopharmacology</i> , 2008 , 197, 401-8	4.7	78
16	Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. <i>Journal of Psychopharmacology</i> , 2007 , 21, 440-52	4.6	283
15	Novel targets for drugs in schizophrenia. <i>CNS and Neurological Disorders - Drug Targets</i> , 2007 , 6, 265-72	2.6	27
14	Antipsychotic drug action: targets for drug discovery with neurochemical imaging. <i>Expert Review of Neurotherapeutics</i> , 2006 , 6, 57-64	4.3	15
13	The contribution of brain imaging to understanding the mechanism of second generation antipsychotic drugs. <i>European Psychiatry</i> , 2006 , 21, 347	6	
12	Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. <i>Nuclear Medicine and Biology</i> , 2006 , 33, 239-43	2.1	30

11	Psychopathological consequences of ketamine. <i>British Journal of Psychiatry</i> , 2006 , 189, 565-6	5.4	12
10	[123I]TPCNE--a novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge. <i>Synapse</i> , 2006 , 60, 109-17	2.4	35
9	First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. <i>Molecular Psychiatry</i> , 2006 , 11, 118-9	15.1	218
8	Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. <i>Biological Psychiatry</i> , 2005 , 58, 41-6	7.9	49
7	Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. <i>Psychopharmacology</i> , 2005 , 180, 664-9	4.7	19
6	[123I]TPCNE: A novel SPET tracer for the sigma-1 receptor is displaceable in humans in vivo with low dose oral haloperidol. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005 , 25, S656-S656	7.3	
5	[123I]TPCNE: A novel SPET tracer for the sigma-1 receptor binds irreversibly in humans in vivo. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005 , 25, S655-S655	7.3	
4	An audit of risk assessment in an emergency setting. <i>Psychiatric Bulletin</i> , 2002 , 26, 88-90		4
3	Naturalistic study of the antipsychotic medication review service at the Maudsley Hospital. <i>Psychiatric Bulletin</i> , 2002 , 26, 291-294		2
2	Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. <i>Journal of Neurochemistry</i> , 1994 , 63, 1987-90	6	282
1	Involvement of the GABA and glutamate neurotransmitter systems in bipolar disorder49-60		